Shell-crosslinked zein nanocapsules for oral codelivery of exemestane and resveratrol in breast cancer therapy

被引：81
作者：
Elzoghby, Ahmed O. [1 ,2 ]
El-Lakany, Sarah A. [2 ]
Helmy, Maged W. [1 ,3 ]
Abu-Serie, Marwa M. [4 ]
Elgindy, Nazik A. [2 ]
机构：
[1] Alexandria Univ, Fac Pharm, CNRL, Alexandria 21521, Egypt
[2] Alexandria Univ, Fac Pharm, Dept Ind Pharm, Alexandria 21521, Egypt
[3] Damanhour Univ, Fac Pharm, Dept Pharmacol & Toxicol, Damanhour, Egypt
[4] City Sci Res & Technol Applicat, Genet Engn & Biotechnol Res Inst, Med Biotechnol Dept, Alexandria 21934, Egypt
来源：
NANOMEDICINE | 2017年 / 12卷 / 24期
关键词：
breast cancer; combined therapy; exemestane; oral delivery; resveratrol; zein nanocapsules; DRUG-DELIVERY; PROTAMINE NANOCAPSULES; GROWTH-FACTOR; NANOPARTICLES; PROTEIN; BIOAVAILABILITY; GLUTARALDEHYDE; FLUTAMIDE; SYSTEM; INHIBITION;
D O I：
10.2217/nnm-2017-0247
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Aim: Oral administration of exemestane (EXM) and resveratrol (RES) for breast cancer therapy has been limited by their poor solubility and low permeability. Methods: In this study, these issues were tackled using zein nanocapsules (ZNCs) for oral EXM/RES codelivery combining drug solubilization within oily core and resistance to digestion via hydrophobic protein shell. Furthermore, higher oral stability and sustained release could be enabled by glutaraldehyde crosslinking of zein shell. Results & conclusion: EXM/RES-ZNCs showed enhanced cytotoxicity against MCF-7 and 4T1 breast cancer cells compared with free drug combination with higher selectivity to cancer cells rather than normal fibroblasts. In vivo, crosslinked EXM/RES-ZNCs markedly reduced the percentage increase of Ehrlich ascites mammary tumor volume in mice by 2.4-fold compared with free drug combination.
引用
收藏
页码：2785 / 2805
页数：21
相关论文
共 62 条
[1]   Investigation of nanocapsules stabilization by amorphous excipients during freeze-drying and storage [J].
Abdelwahed, Wassim ;
Degobert, Ghania ;
Fessi, Hatem .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2006, 63 (02) :87-94
[2]   Optimization of caseinate-coated simvastatin-zein nanoparticles: improved bioavailability and modified release characteristics [J].
Ahmed, Osama A. A. ;
Hosny, Khaled M. ;
Al-Sawahli, Majid M. ;
Fahmy, Usama A. .
DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 :655-662
[3]  
Badisa RB, 2009, ANTICANCER RES, V29, P2993
[4]   Current methodologies used for evaluation of intestinal permeability and absorption [J].
Balimane, PV ;
Chong, SH ;
Morrison, RA .
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 2000, 44 (01) :301-312
[5]  
Bhat KPL, 2001, CANCER RES, V61, P7456
[6]  
Byrne GJ, 2007, ANTICANCER RES, V27, P3481
[7]   Functionalized Positive Nanoparticles Reduce Mucin Swelling and Dispersion [J].
Chen, Eric Y. T. ;
Wang, Yung-Chen ;
Chen, Chi-Shuo ;
Chin, Wei-Chun .
PLOS ONE, 2010, 5 (11)
[8]   HPLC Methods for Quantitation of Exemestane-Luteolin and Exemestane-Resveratrol Mixtures in Nanoformulations [J].
El-lakany, Sarah A. ;
Elzoghby, Ahmed O. ;
Elgindy, Nazik A. ;
Hamdy, Dalia A. .
JOURNAL OF CHROMATOGRAPHIC SCIENCE, 2016, 54 (08) :1282-1289
[9]  
Elgindy N, 2012, J NANOMED NANOTECHNO, V2, P110
[10]   A bluiti-layered Particulate System for Desvenlafaxine Succinate Oral Customized Release [J].
Elgindy, Nazik ;
Elnoby, Ayman ;
El-Gowelli, Hanan M. ;
Samy, Wael .
CURRENT DRUG DELIVERY, 2017, 14 (03) :416-425
1234567